- Home
- ROIV vs EDU Comparison
ROIV vs EDU Comparison
Compare ROIV & EDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- EDU
- Stock Information
- Founded
- ROIV 2014
- EDU 1993
- Country
- ROIV United Kingdom
- EDU China
- Employees
- ROIV N/A
- EDU N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- EDU Other Consumer Services
- Sector
- ROIV Health Care
- EDU Real Estate
- Exchange
- ROIV Nasdaq
- EDU Nasdaq
- Market Cap
- ROIV 8.6B
- EDU 8.5B
- IPO Year
- ROIV N/A
- EDU 2006
- Fundamental
- Price
- ROIV $16.26
- EDU $52.65
- Analyst Decision
- ROIV Strong Buy
- EDU Buy
- Analyst Count
- ROIV 8
- EDU 6
- Target Price
- ROIV $19.94
- EDU $56.87
- AVG Volume (30 Days)
- ROIV 8.5M
- EDU 955.3K
- Earning Date
- ROIV 11-11-2025
- EDU 10-28-2025
- Dividend Yield
- ROIV N/A
- EDU N/A
- EPS Growth
- ROIV N/A
- EDU 27.50
- EPS
- ROIV N/A
- EDU 2.29
- Revenue
- ROIV $23,233,000.00
- EDU $4,900,262,000.00
- Revenue This Year
- ROIV N/A
- EDU $9.40
- Revenue Next Year
- ROIV $200.91
- EDU $9.92
- P/E Ratio
- ROIV N/A
- EDU $22.41
- Revenue Growth
- ROIV N/A
- EDU 13.60
- 52 Week Low
- ROIV $8.73
- EDU $40.66
- 52 Week High
- ROIV $16.79
- EDU $75.08
- Technical
- Relative Strength Index (RSI)
- ROIV 74.57
- EDU 55.15
- Support Level
- ROIV $15.91
- EDU $50.88
- Resistance Level
- ROIV $16.39
- EDU $53.85
- Average True Range (ATR)
- ROIV 0.45
- EDU 1.44
- MACD
- ROIV -0.03
- EDU -0.19
- Stochastic Oscillator
- ROIV 76.64
- EDU 44.69
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.